Glenmark Pharmaceuticals Limited - Balance (Quarterly)

Glenmark Pharmaceuticals Limited
IN ˙ NSEI ˙ INE935A01035
2.404,95 ₹ ↑80,10 (3,45%)
2026-04-28
DEL PRIS
Balance (Quarterly)

Glenmark Pharmaceuticals Limited Balance viser kontosaldi for virksomheden på tidspunkter. Balancedata inkluderer aktiver, omsætningsaktiver, anlægsaktiver, materielle anlægsaktiver (PPE), inventar, immaterielle aktiver, passiver, kortfristede forpligtelser, gæld, kapitalleasingforpligtelser, almindelige aktier, overført overskud, egne aktier og egenkapital.

Alle tal er gange 1,000,000.00 undtagen pr. andel enheder.

2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
2025
09-30
Kontanter 14.296 14.105 12.400 11.592 11.240 16.583 18.202 16.757 26.902
Ændring (%) -1,34 -12,09 -6,52 -3,04 47,53 9,77 -7,94 60,54
Aktiver Nuværende 80.732 82.823 89.592 107.255 112.669 74.281 90.335 92.955 114.532
Ændring (%) 2,59 8,17 19,71 5,05 -34,07 21,61 2,90 23,21
Aktiver 166.135 170.833 180.308 193.717 200.064 143.586 152.353 160.496 190.020
Ændring (%) 2,83 5,55 7,44 3,28 -28,23 6,11 5,34 18,40
Forpligtelser 76.135 76.452 80.916 95.324 102.707 65.111 67.898 72.005 94.204
Ændring (%) 0,42 5,84 17,81 7,75 -36,61 4,28 6,05 30,83
Egenkapital 89.999 94.381 99.392 98.393 97.357 78.475 84.455 88.491 95.816
Ændring (%) 4,87 5,31 -1,01 -1,05 -19,39 7,62 4,78 8,28
Passiver og Aktiekapital 166.135 170.833 180.308 193.717 200.064 143.586 152.353 160.496 190.020
Ændring (%) 2,83 5,55 7,44 3,28 -28,23 6,11 5,34 18,40

Source: Capital IQ

Other Listings
IN:532296 2.410,60 ₹
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista